Products
Data
Feature
Plans
Request Demo
Sign Up for Free
Blog
Valuable Targets
Advanced Tech.
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
SEMA4A Biologics Sequence Review Report 2026: Semaphorin-4A Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of SEMA4A protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
8 min read
SEMA3G Biologics Sequence Review Report 2026: Semaphorin-3G Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of SEMA3G protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
8 min read
SEMA4C Biologics Sequence Review Report 2026: Semaphorin-4C Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of SEMA4C protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
8 min read
SEMA3F Biologics Sequence Review Report 2026: Semaphorin-3F Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of SEMA3F protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
8 min read
SEMA3D Biologics Sequence Review Report 2026: Semaphorin-3D Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of SEMA3D protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
8 min read
SEMA3E Biologics Sequence Review Report 2026: Semaphorin-3E Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of SEMA3E protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
8 min read
SEMA3C Biologics Sequence Review Report 2026: Semaphorin-3C Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of SEMA3C protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
8 min read
SCARF1 Biologics Sequence Review Report 2026: Scavenger receptor class F member 1 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of SCARF1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
8 min read
SEMA3B Biologics Sequence Review Report 2026: Semaphorin-3B Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of SEMA3B protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
8 min read
SEMA3A Biologics Sequence Review Report 2026: Semaphorin-3A Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of SEMA3A protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
8 min read
SCARF2 Biologics Sequence Review Report 2026: Scavenger receptor class F member 2 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of SCARF2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
8 min read
MMP17 Biologics Sequence Review Report 2026: Matrix metalloproteinase-17 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of MMP17 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
<
1
<<
168
169
170
171
172
>>
1670
>